Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altimmune Inc
(NQ:
ALT
)
7.080
-0.490 (-6.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,205,235
Open
7.550
Bid (Size)
7.030 (1)
Ask (Size)
7.150 (11)
Prev. Close
7.570
Today's Range
6.980 - 7.750
52wk Range
2.090 - 14.84
Shares Outstanding
70,895,286
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Today 6:33 EDT
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Via
InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
April 22, 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
Via
MarketBeat
Performance
YTD
-32.70%
-32.70%
1 Month
-17.00%
-17.00%
3 Month
-29.34%
-29.34%
6 Month
+200.00%
+200.00%
1 Year
+28.26%
+28.26%
More News
Read More
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
April 20, 2024
Via
The Motley Fool
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
April 11, 2024
Via
InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
April 09, 2024
Via
The Motley Fool
How Is The Market Feeling About Altimmune?
April 08, 2024
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
April 03, 2024
Via
Benzinga
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
March 27, 2024
Via
InvestorPlace
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 09, 2024
Via
MarketBeat
Exposures
Product Safety
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 28, 2024
Via
Benzinga
Altimmune's Earnings Outlook
March 26, 2024
Via
Benzinga
(ALT) - Analyzing Altimmune's Short Interest
March 22, 2024
Via
Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
March 18, 2024
Via
Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
March 28, 2024
Via
Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
March 28, 2024
Via
Investor's Business Daily
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
Via
MarketBeat
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
March 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 27, 2024
Via
Benzinga
Earnings Scheduled For March 27, 2024
March 27, 2024
Via
Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
March 19, 2024
Via
Benzinga
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
March 15, 2024
Via
The Motley Fool
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 03, 2024
Via
NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 03, 2024
Via
TheNewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 01, 2024
Via
NewMediaWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 01, 2024
Via
TheNewswire.com
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.